
UNITED STA	ATES PATENT AND TRADEMARK OFFICE
BEFORE TH	HE PATENT TRIAL AND APPEAL BOARD
SAW	SAWAI USA, INC. AND WAI PHARMACEUTICAL CO., LTD. Petitioners,
	V.
	BIOGEN MA, INC. Patent Owner.
	Patent No. 8,399,514
In	nter Partes Review IPR2019-00789

EXPERT DECLARATION OF ROBERT WALTER BAUMHEFNER, M.D. IN SUPPORT OF PETITION FOR *INTER PARTES* REVIEW OF U.S. PATENT NO. 8,399,514



TABLE OF CONTENTS


			Page
I.	QUA	ALIFICATIONS AND BACKGROUND	5
	A.	Education and Experience; Prior Testimony	5
	B.	Bases for Opinions and Materials Considered	6
	C.	Scope of Work	6
II.	SUN	MMARY OF OPINIONS	7
III.	LEGAL STANDARDS		
IV.	PERSON OF ORDINARY SKILL IN THE ART		
V.	THE	E '514 PATENT (EX. 1001)	12
	A.	Claims of the '514 Patent	12
VI.	CLAIM CONSTRUCTION		14
VII.	BAG	CKGROUND	15
	A.	Multiple Sclerosis	15
	B.	Multiple Sclerosis Therapies	20
VIII.	SCC	PPE AND CONTENT OF THE PRIOR ART REFERENCES	22
	A.	Schimrigk 2004 Abstract	22
	B.	Schimrigk 2004 Poster	24
	C.	Brune 2004	25
	D.	Schimrigk 2005 Abstract	26
	E.	Kappos 2005	27
	F.	January 2006 Biogen Press Release	28
	G.	May 2006 Biogen Press Release	29
	Н.	Kappos 2006	30
	I.	WO '342	31
	J.	Nieboer 1990	32
	K.	Schimrigk 2006	34
	L.	Mrowietz 2005	35
	M.	Fumaderm® Label	36



	N.	Ockenfels 1998	37
	O.	de Jong 1996	38
	P.	Nibbering 1993	39
	Q.	Clinical Trials	40
	R.	ICH Guidelines	40
	S.	Joshi Patents	41
	T.	Biogen 2005 Press Release	42
	U.	Ormerod 2004	43
	V.	Mrowietz 1998	44
	W.	Additional prior art references and knowledge	44
IX.	UNP	UNPATENTABILITY OF THE '514 PATENT	
	A.	The Claims of the '514 Patent are Obvious over the January 2006 Biogen Press Release in view of the Schimrigk 2004 Abstract	45
		1. Independent Claims 1, 11, 15, and 20	45
		2. Dependent Claims	62
	B.	The Claims of the '514 Patent are Obvious over Kappos 2006 in view of the Schimrigk 2004 Abstract	66
		1. Independent Claims 1, 11, 15, and 20	66
		2. Dependent claims	74
	C.	The Claims of the '514 Patent are Obvious over Kappos 2006 in view of WO '342	74
		1. Independent Claims 1, 11, 15, and 20	74
		2. Dependent claims	76
	D.	The Claims of the '514 Patent are Obvious over Kappos 2006, Clinical Trials, Joshi '999, and ICH Guidelines	76
		1. Independent Claims 1, 11, 15, and 20	76
		2 Dependent claims	82



	The	re Are No Secondary Considerations of Nonobviousness	82
	1.	The invention claimed in the '514 patent did not achieve	
		unexpected results	82
	2.	The invention claimed in the '514 patent did not fill a long	-felt
		hut unmet need	89



1. My name is Robert Walter Baumhefner, M.D. I have been retained by counsel for Sawai USA, Inc. and Sawai Pharmaceutical Co., Ltd. ("Sawai"). I understand that Sawai intends to petition for *inter partes* review ("IPR") of U.S. Patent No. 8,399,514 ("the '514 patent"), Ex. 1001, which is assigned to Biogen MA Inc. I also understand that Sawai will request that the United States Patent and Trademark Office cancel all claims of the '514 patent as unpatentable in such IPR petition. I submit this expert declaration, which addresses and supports Sawai's IPR petition for the '514 patent.

II. QUALIFICATIONS AND BACKGROUND

A. Education and Experience; Prior Testimony

- 2. I received my B.A. in Biochemistry from the University of California in 1970 and my M.D. from Northwestern University in 1974. I did a residency in Neurology at Harbor General Hospital from 1975-1978 and was a Research Fellow in Multiple Sclerosis from 1978-1980. In 1980, I became a Staff Physician at VA West Los Angeles Medical Center, where I am still employed today as an Instructor and Attending Neurologist.
- 3. I served as Chairman of the Clinical Advisory Committee of the Los Angeles Chapter of the National Multiple Sclerosis Society from 1995-1999, Codirector of the National Neurological Research Specimen Bank at the VA West Los



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

